Abstract 368P
Background
Breast cancer is the leading cause of cancer death among women, and incidence in Asia is increasing in large part because of changes in reproductive and lifestyle factors. Several appreciable differences exist between breast cancers in Asian and Caucasian women. For example, Asians have a younger median age of incidence and correspondingly, a higher prevalence of hereditary factors, and together, these suggest that they may be crucial differences at the molecular level.
Methods
We performed whole exome sequencing (WES) on 576 Malaysian breast cancers (at median coverage 75X) and their matched normal blood (40X) to detect single nucleotide variations (SNVs) and small insertions and deletions (indels). We also performed shallow whole genome sequencing (sWGS) to detect major chromosomal aberrations, and transcriptomic sequencing (RNA-seq) to measure gene expression.
Results
We captured known copy number changes, together with major breast cancer genes and their phenotypes, for example high frequency of SNVs in hotspot regions in PIK3CA and indels in GATA3. Interestingly, Malaysian breast cancer show higher prevalence of Her2+ molecular subtypes and TP53 mutations, as well as higher immune scores compared with Caucasian breast cancer cases, consistent with previous findings in other smaller Asian datasets.
Conclusions
Our report of the hitherto largest dataset of genomic profiling of Asian breast cancers show the molecular differences between Asian and Caucasian breast cancers and point to potential differences in therapy and outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Cancer Research Malaysia.
Funding
Cancer Research Malaysia, Medical Research Council Newton Ungku Omar Fund, Scientex Foundation, Estee Lauder Breast Cancer Campaign, Yayasan Sime Darby, Yayasan Petronas.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract